FourThought Financial LLC Has $442,000 Stake in Novo Nordisk A/S (NYSE:NVO)

FourThought Financial LLC lessened its holdings in Novo Nordisk A/S (NYSE:NVO – Get Rating) by 10.5% during the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 4,434 shares of the company’s stock after selling 522 shares during the period. FourThought Financial LLC’s holdings in Novo Nordisk A/S were worth $442,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of NVO. BlackRock Inc. boosted its stake in shares of Novo Nordisk A/S by 45.4% in the 1st quarter. BlackRock Inc. now owns 5,035,879 shares of the company’s stock worth $559,235,000 after buying an additional 1,571,747 shares during the last quarter. WCM Investment Management LLC boosted its stake in shares of Novo Nordisk A/S by 35.1% in the 2nd quarter. WCM Investment Management LLC now owns 3,850,053 shares of the company’s stock worth $423,814,000 after buying an additional 999,342 shares during the last quarter. Eaton Vance Management boosted its stake in shares of Novo Nordisk A/S by 289.1% in the 3rd quarter. Eaton Vance Management now owns 1,088,926 shares of the company’s stock worth $108,489,000 after buying an additional 809,078 shares during the last quarter. First Trust Advisors LP boosted its stake in shares of Novo Nordisk A/S by 36,122.5% in the 3rd quarter. First Trust Advisors LP now owns 669,754 shares of the company’s stock worth $66,727,000 after buying an additional 667,905 shares during the last quarter. Finally, Healthcare of Ontario Pension Plan Trust Fund purchased a new position in shares of Novo Nordisk A/S in the 2nd quarter worth approximately $69,488,000. Hedge funds and other institutional investors own 6.09% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the company. StockNews.com assumed coverage on Novo Nordisk A/S in a research note on Thursday. They issued a “strong-buy” rating on the stock. Cowen upped their price objective on Novo Nordisk A/S from $130.00 to $145.00 in a research note on Monday, December 12th. Cowen upped their price objective on Novo Nordisk A/S from $130.00 to $145.00 in a research note on Monday, December 12th. Finally, JPMorgan Chase & Co. upped their price objective on Novo Nordisk A/S from 925.00 to 1,100.00 and gave the company an “overweight” rating in a research note on Tuesday, January 3rd. One investment analyst has rated the stock with a sell rating, four have given a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Novo Nordisk A/S currently has a consensus rating of “Moderate Buy” and a consensus target price of $697.78.

Novo Nordisk A/S Trading Down 1.5 %

Shares of NVO stock opened at $138.89 on Friday. The stock has a market capitalization of $314.30 billion, a price-to-earnings ratio of 40.03, a PEG ratio of 1.48 and a beta of 0.47. Novo Nordisk A/S has a 1 year low of $95.02 and a 1 year high of $145.94. The company’s fifty day simple moving average is $139.95 and its two-hundred day simple moving average is $123.23. The company has a debt-to-equity ratio of 0.29, a current ratio of 0.89 and a quick ratio of 0.69.

Novo Nordisk A/S Increases Dividend

The company also recently declared a semi-annual dividend, which will be paid on Tuesday, April 4th. Stockholders of record on Monday, March 27th will be issued a $1.1887 dividend. The ex-dividend date of this dividend is Friday, March 24th. This represents a dividend yield of 0.8%. This is a boost from Novo Nordisk A/S’s previous semi-annual dividend of $0.58. Novo Nordisk A/S’s dividend payout ratio is presently 23.34%.

Novo Nordisk A/S Company Profile

(Get Rating)

Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharm segments. The Diabetes and Obesity Care segment includes insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD), obesity, and other serious chronic diseases.